Browse EX-10 agreements

EXECUTION VERSION

LETTER AGREEMENT

October 12, 2026

Reference is made to that certain letter agreement dated January 29, 2026 relating to the initial public offering of M Evo Global Acquisition Corp II, a Cayman Islands exempted company (the “Company”), by and among the Company, the sponsor and the insiders party thereto, a copy of which is attached hereto as Exhibit A (the “Existing Letter Agreement”). This letter agreement (this “Letter Agreement”) is executed in connection with the appointment of Richard Majlinder (the “Director”) to the Company’s board of directors. This Letter Agreement is a separate agreement between the Director and the Company and does not amend the Existing Letter Agreement or make the Director a party thereto. Subsequent amendments to the Existing Letter Agreement shall not affect the terms incorporated into this Letter Agreement unless the Director and the Company otherwise agree in writing. Capitalized terms used but not otherwise defined herein have the meanings assigned to them in the Existing Letter Agreement.

…

EXECUTION VERSION

INDEMNITY AGREEMENT

October 12, 2026

Reference is made to that certain Indemnity Agreement, dated as of January 29, 2026, by and between M Evo Global Acquisition Corp II, a Cayman Islands exempted company (the “Company”), and the undersigned indemnitees thereto, a copy of which is attached hereto as Exhibit A (the “Existing Indemnity Agreement”). This indemnity agreement (this “Indemnity Agreement”) is executed in connection with the appointment of Richard Majlinder (the “Director”) to the Company’s board of directors. This Indemnity Agreement is a separate agreement between the Director and the Company and does not amend the Existing Indemnity Agreement or make the Director a party thereto. Subsequent amendments to the Existing Indemnity Agreement shall not affect the terms incorporated into this Indemnity Agreement unless the Director and the Company otherwise agree in writing. Capitalized terms used but not otherwise defined herein have the meanings assigned to them in the Existing Indemnity Agreement.

…

Senior Secured Convertible Note

** **

THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY THIS SECURITY.

Original Issue Date: October 6, 2026	Funding Amount	$ 5,000,000
Final Maturity Date: March 24, 2027	Original Principal Amount:	$ 6,750,000

CDT EQUITY INC.

…

PAID-IN-FULL ACKNOWLEDGMENT

Unsecured Revolving Line of Credit

Date: October 9, 2026

Lender: Larry Powalisz, Chief Executive Officer

Borrower: Adia Med, Inc. (and its relevant subsidiaries, as applicable)

Original Facility Date: June 30, 2024

Acknowledgment

Reference is made to the unsecured revolving line of credit facility originally dated June 30, 2024, as increased most recently to a commitment of $1,000,000, bearing interest at 6% per annum calculated daily, between Larry Powalisz, as lender, and Adia Med, Inc., as borrower.

The Lender acknowledges receipt and application of the following payments from the Borrower:

…

Execution Version

| |

…

THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

** **

PROMISSORY NOTE

** **

Principal Amount: US$8,253.03

Dated: October 7, 2026

New York, New York

…

THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

** **

PROMISSORY NOTE

** **

Principal Amount: US$8,253.03

Dated: October 7, 2026

New York, New York

…

MUELLER WATER PRODUCTS, INC.

October 2, 2026

Mike Morgan - Offer of Employment

Dear Mike,

On behalf of Mueller (“Company”), I am very pleased to extend you an offer to join the Company as Executive Vice President, Finance, effective October 28, 2026, and Executive Vice President and Chief Financial Officer, effective upon filing of our FY2026 Annual Report, which anticipated filing date is November 18, 2026. As you will appreciate, this two-step process is driven by securities requirements and will not impact your compensation or responsibilities. In your role you will be reporting directly to me.

Mike, I am excited about the opportunity to have you join our executive leadership team. We are confident that your experience, leadership and track record will be instrumental as we execute Mueller’s strategy and continue to strengthen our financial and operational performance. I look forward to having you as a key partner to me, the Board and our leadership team as we enter Mueller’s next phase of profitable growth and value creation.

…

TRANSITION AGREEMENT

This Transition Agreement (this “Agreement”) is entered into as of October 12, 2026 (the “Effective Date”) by and between Melissa Rasmussen (the “Executive”) and Mueller Water Products, Inc., a Delaware corporation (the “Company”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Company’s Executive Severance Plan dated January 1, 2020, as amended (the “Plan”).

WHEREAS, the Executive currently serves as the Senior Vice President and Chief Financial Officer of the Company;

WHEREAS, the Executive is a participant in the Plan;

WHEREAS, the Executive and the Company desire to transition the Executive to the role of Senior Advisor and resolve any outstanding matters related to the Executive’s subsequent termination of employment with the Company.

NOW, THEREFORE, for the promises and covenants set forth herein and for such other good and valuable consideration, the receipt of which is hereby acknowledged, the Executive and the Company enter into this Agreement on the following terms and conditions:

…

Execution Version THIS RESTRUCTURING SUPPORT AGREEMENT IS NOT AN OFFER OR ACCEPTANCE WITH RESPECT TO ANY SECURITIES OR A SOLICITATION OF ACCEPTANCES OF A CHAPTER 11 PLAN WITHIN THE MEANING OF SECTION 1125 OF THE BANKRUPTCY CODE. ANY SUCH OFFER OR SOLICITATION WILL COMPLY WITH ALL APPLICABLE SECURITIES LAWS AND/OR PROVISIONS OF THE BANKRUPTCY CODE. NOTHING CONTAINED IN THIS RESTRUCTURING SUPPORT AGREEMENT SHALL BE AN ADMISSION OF FACT OR LIABILITY OR, UNTIL THE OCCURRENCE OF THE AGREEMENT EFFECTIVE DATE ON THE TERMS DESCRIBED HEREIN, DEEMED BINDING ON ANY OF THE PARTIES HERETO. THIS RESTRUCTURING SUPPORT AGREEMENT IS THE PRODUCT OF SETTLEMENT DISCUSSIONS AMONG THE PARTIES HERETO. ACCORDINGLY, THIS RESTRUCTURING SUPPORT AGREEMENT IS PROTECTED BY RULE 408 OF THE FEDERAL RULES OF EVIDENCE AND ANY OTHER APPLICABLE STATUTES OR DOCTRINES PROTECTING THE USE OR DISCLOSURE OF CONFIDENTIAL SETTLEMENT DISCUSSIONS. THIS RESTRUCTURING SUPPORT AGREEMENT DOES NOT PURPORT TO SUMMARIZE ALL OF THE TERMS, CONDITIONS, REPRESENTATIONS, WARRANTIES, AND OTHER PROVISIONS WITH RESPECT TO THE TRANSACTIONS DESC

…

AMENDMENT NO. 2 TO PURCHASE AND SALE AGREEMENT

This Amendment No. 2 to Purchase and Sale Agreement (this “Amendment”), dated as of October 7, 2026, is made and entered into by and between ADC THERAPEUTICS SA, a Swiss *société anonyme *(the “Seller”), and the entities managed by Healthcare Royalty Management, LLC listed on the signature pages hereto and on Exhibit F to the Agreement (collectively, the “Buyer”); provided that, for purposes of this Amendment and the Amendment No. 1 Warrants, “Buyer” shall include each Person executing this Amendment in its capacity as a Buyer or Warrantholder.

RECITALS:

WHEREAS, the Seller and the Buyer are parties to that certain Purchase and Sale Agreement, dated as of August 25, 2021 (the “Agreement”);

WHEREAS, the Buyer has previously paid the Closing Price and the EMA Milestone Payment, comprising an aggregate Purchase Price of $300,000,000 in total;

…

** **

---

AMENDMENT TO WARRANT TO PURCHASE COMMON SHARES OF ADC THERAPEUTICS SA

This Amendment to the Warrant to Purchase Common Shares of ADC Therapeutics SA (the “Amendment”), is dated October 7, 2026, and is made between ADC Therapeutics SA, a Swiss stock corporation (société anonyme) organized under the laws of Switzerland (the “Company”), and [W-L-1: BLUE OWL OPPORTUNISTIC LENDING MASTER FUND II, L.P.] [W-L-2: BLUE OWL OPPORTUNISTIC LENDING DL (C), L.P.] [W-L-3: OAKTREE LSL FUND HOLDINGS EURRC S.à r.l] [W-L-4: OAKTREE STRATEGIC CREDIT FUND] [W-L-5: OAKTREE AZ STRATEGIC LENDING FUND, L.P.] [W-L-6: OAKTREE SPECIALTY LENDING CORPORATION] [W-L-7: OAKTREE LSL HOLDINGS EURRC S.À R.L.] [W-L-8: OAKTREE DIVERSIFIED INCOME FUND, INC.] or its registered assign (the “Warrantholder”).

…